BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Werner CR, Schwarz JM, Egetemeyr DP, Beck R, Malek NP, Lauer UM, Berg CP. Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12. World J Gastroenterol 2016; 22(35): 8050-8059 [PMID: 27672299 DOI: 10.3748/wjg.v22.i35.8050]
URL: https://www.wjgnet.com/1948-5182/full/v22/i35/8050.htm
Number Citing Articles
1
Christina Sølund, Sofie Hallager, Martin S. Pedersen, Ulrik Fahnøe, Anja Ernst, Henrik B. Krarup, Birgit T. Røge, Peer B. Christensen, Alex L. Laursen, Jan Gerstoft, Erika Bélard, Lone G. Madsen, Kristian Schønning, Anders G. Pedersen, Jens Bukh, Nina Weis. Direct acting antiviral treatment of chronic hepatitis C in Denmark: factors associated with and barriers to treatment initiationScandinavian Journal of Gastroenterology 2018; 53(7): 849 doi: 10.1080/00365521.2018.1467963
2
Saima Mushtaq, Tayyab Saeed Akhter, Amjad Khan, Aamir Sohail, Arshad Khan, Sobia Manzoor. Efficacy and Safety of Generic Sofosbuvir Plus Daclatasvir and Sofosbuvir/Velpatasvir in HCV Genotype 3-Infected Patients: Real-World Outcomes From PakistanFrontiers in Pharmacology 2020; 11 doi: 10.3389/fphar.2020.550205
3
M G Artemova, D T Abdurakhmanov. Cryoglobulinemic vasculitis in chronic hepatitis C: Genetic aspectsTerapevticheskii arkhiv 2017; 89(4): 110 doi: 10.17116/terarkh2017894110-114
4
Paula Eckardt, Jianli Niu, Angela Savage, Tara Griffin, Elizabeth Sherman. Effect of Health Insurance on Hepatitis C Sustained Virologic Response Rates to Sofosbuvir-Based Treatment Regimens in a South Florida Community HospitalJournal of the International Association of Providers of AIDS Care (JIAPAC) 2019; 18: 232595821983559 doi: 10.1177/2325958219835590
5
Thalia Medeiros, Camila de Morais Salviato, Natalia Fonseca do Rosário, Geórgia do Nascimento Saraiva, Eliane Bordalo Cathalá Esberard, Jorge Reis Almeida, Analúcia Rampazzo Xavier, Andrea Alice da Silva. Adverse effects of direct acting antiviral-based regimens in chronic hepatitis C patients: a Brazilian experienceInternational Journal of Clinical Pharmacy 2017; 39(6): 1304 doi: 10.1007/s11096-017-0552-1
6
Simeprevir/sofosbuvirReactions Weekly 2016; 1627(1): 131 doi: 10.1007/s40278-016-22875-5
7
Frank A. Fanizza, Jennifer Loucks, Angelica Berni, Meera Shah, Dennis Grauer, Sarah Daniel. Patient Access to Hepatitis C Treatment After Incorporation of Pharmacists in a Hepatology ClinicHospital Pharmacy 2022; 57(3): 370 doi: 10.1177/00185787211037540
8
Vijay Gayam, Muhammad Rajib Hossain, Mazin Khalid, Sandipan Chakaraborty, Osama Mukhtar, Sumit Dahal, Amrendra Kumar Mandal, Arshpal Gill, Pavani Garlapati, Sreedevi Ramakrishnaiah, Khalid Mowyad, Jagannath Sherigar, Mohammed Mansour, Smruti Mohanty. Real-World Clinical Efficacy and Tolerability of Direct-Acting Antivirals in Hepatitis C Monoinfection Compared to Hepatitis C/Human Immunodeficiency Virus Coinfection in a Community Care SettingGut and Liver 2018; 12(6): 694 doi: 10.5009/gnl18004
9
Tchadine Djaogol, Hélène Fontaine, Maël Baudoin, Camelia Protopopescu, Fabienne Marcellin, Céline Dorival, Mélanie Simony, Ventzislava Petrov‐Sanchez, Marc Bourlière, Elisabeth Delarocque‐Astagneau, Stanislas Pol, Fabrice Carrat, Patrizia Carrieri. Effectiveness of direct‐acting antivirals for chronic hepatitis C treatment in migrant and non‐migrant populations in FranceLiver International 2021; 41(10): 2328 doi: 10.1111/liv.14823
10
Lone Wulff Madsen, Peer Brehm Christensen, Anne Øvrehus, Dorthe Marie Sjødahl Bryde, Dorte Kinggaard Holm, Søren Thue Lillevang, Christian Nielsen. Immunological Characteristics of Patients Receiving Ultra-Short Treatment for Chronic Hepatitis CFrontiers in Cellular and Infection Microbiology 2022; 12 doi: 10.3389/fcimb.2022.885824
11
Lijoy Varghese, Sharifa Ezat Wan Puteh, Nadia Schecroun, Rohani Jahis, Ilse Van Vlaenderen, Baudouin A. Standaert. Applying a Constrained Optimization Portfolio Model to Aid Prioritization of Public Health Interventions in MalaysiaValue in Health Regional Issues 2020; 21: 172 doi: 10.1016/j.vhri.2019.11.001
12
Vered Richter, Liav Goldstein, Daniel L Cohen, Anton Bermont, Dana Zelnik Yovel, Miriam Madar, Ron Rabinovitch, Haim Shirin, Efrat Broide. The effect of direct-acting antiviral regimens and telemedicine on the treatment of inmates with hepatitis C virus infection in Israeli prisonsScience Progress 2022; 105(2): 003685042211051 doi: 10.1177/00368504221105173
13
Jianhong Chen, Xiaxia Zhang, Hao Luo, Chihong Wu, Min Yu, Dan Liu, Hongli Xi, Yihang Zhou, Yaoyu An, Xiaoyuan Xu. Changes in renal function indices in cirrhotic chronic hepatitis C patients treated with sofosbuvir-containing regimensOncotarget 2017; 8(53): 90916 doi: 10.18632/oncotarget.18701
14
Giuseppe Bruno, Annalisa Saracino, Luigia Scudeller, Claudia Fabrizio, Raffaele Dell’Acqua, Eugenio Milano, Michele Milella, Nicoletta Ladisa, Laura Monno, Gioacchino Angarano. HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ?International Journal of Infectious Diseases 2017; 62: 64 doi: 10.1016/j.ijid.2017.07.001
15
Mohammad Saeid Rezaee-Zavareh, Khashayar Hesamizadeh, Heidar Sharafi, Seyed Moayed Alavian. Treatment of Hepatitis C Infection with Direct-Acting Antiviral Agents in Liver-Transplant Patients: A Systematic Review and Meta-AnalysisHepatitis Monthly 2017; 17(6) doi: 10.5812/hepatmon.12324
16
Kimberly E. Daniel, Kia Saeian, Syed Rizvi. Real‐world experiences with direct‐acting antiviral agents for chronic hepatitis C treatmentJournal of Viral Hepatitis 2020; 27(2): 195 doi: 10.1111/jvh.13218
17
Sheng Tang, Zong-Gen Peng, Ying-Hong Li, Xin Zhang, Tian-Yun Fan, Jian-Dong Jiang, Yan-Xiang Wang, Dan-Qing Song. Synthesis and biological evaluation of tricyclic matrinic derivatives as a class of novel anti-HCV agentsChemistry Central Journal 2017; 11(1) doi: 10.1186/s13065-017-0327-8
18
Jeffrey W Jansen, Travis W Linneman, Gillian M Powderly, Ryan P Moenster, Leela Nayak. Association Between Baseline Creatinine Clearance and Treatment Failure in Patients With Hepatitis C Virus Treated With Ledipasvir and SofosbuvirOpen Forum Infectious Diseases 2019; 6(3) doi: 10.1093/ofid/ofz087
19
Sreekumar Othumpangat, Sidhartha D. Ray, John D. Noti. A Worldwide Yearly Survey of New Data in Adverse Drug ReactionsSide Effects of Drugs Annual 2017; 39: 269 doi: 10.1016/bs.seda.2017.07.002
20
Julia L. Casey, Jordan J. Feld, Sonya A. MacParland. Restoration of HCV-Specific Immune Responses with Antiviral Therapy: A Case for DAA Treatment in Acute HCV InfectionCells 2019; 8(4): 317 doi: 10.3390/cells8040317
21
Daniele Lapa, Paola Del Porto, Claudia Minosse, Gianpiero D’Offizi, Andrea Antinori, Maria Rosaria Capobianchi, Ubaldo Visco-Comandini, Fiona McPhee, Anna Rosa Garbuglia, Mauro Zaccarelli. Clinical Relevance of Torque Teno Virus (TTV) in HIV/HCV Coinfected and HCV Monoinfected Patients Treated with Direct-Acting Antiviral TherapyJournal of Clinical Medicine 2021; 10(10): 2092 doi: 10.3390/jcm10102092
22
Muhammad H. Bashir, Javid Fazili, Mohammad F. Madhoun, Rajesh Kanagala, Sixia Chen, Salman Nusrat. Impact of sustained virologic response on short-term clinical outcomes in hepatitis C-related cirrhosisEuropean Journal of Gastroenterology & Hepatology 2018; 30(3): 296 doi: 10.1097/MEG.0000000000001032
23
Marwa K. Ibrahim, Mohamed AbdElrahman, Noha G. Bader El Din, Salwa Tawfik, Sherief Abd-Elsalam, Dalia Omran, Amal Z. Barakat, Sally Farouk, Hassan Elbatae, Mostafa K. El Awady. The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patientsMicrobial Pathogenesis 2022; 162: 105311 doi: 10.1016/j.micpath.2021.105311
24
Julia M. Grottenthaler, Christoph R. Werner, Martina Steurer, Ulrich Spengler, Thomas Berg, Cornelius Engelmann, Heiner Wedemeyer, Thomas von Hahn, Wolfgang Stremmel, Anita Pathil, Ulrich Seybold, Eckart Schott, Usha Blessin, Christoph Sarrazin, Martin-Walter Welker, Ellen Harrer, Stefan Scholten, Clemens Hinterleitner, Ulrich M. Lauer, Nisar P. Malek, Christoph P. Berg, Chen-Hua Liu. Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantationPLOS ONE 2018; 13(6): e0197544 doi: 10.1371/journal.pone.0197544
25
Jeffrey W. Jansen, Gillian M. Powderly, Travis W. Linneman. Identification of Predictors for Treatment Failure in Hepatitis C Virus Patients Treated With Ledipasvir and SofosbuvirAnnals of Pharmacotherapy 2017; 51(7): 543 doi: 10.1177/1060028017693348
26
Timothy Papaluca, Marie Sinclair, Paul Gow, Stephen Pianko, William Sievert, Niranjan Arachchi, Karla Cameron, Scott Bowden, Jacinta O’Keefe, Joseph Doyle, Mark Stoove, Margaret Hellard, David Iser, Alexander Thompson. Retreatment with elbasvir, grazoprevir, sofosbuvir ± ribavirin is effective for GT3 and GT1/4/6 HCV infection after relapseLiver International 2019; 39(12): 2285 doi: 10.1111/liv.14201
27
Stefania Paolucci, Marta Premoli, Stefano Novati, Roberto Gulminetti, Renato Maserati, Giorgio Barbarini, Paolo Sacchi, Antonio Piralla, Davide Sassera, Leone De Marco, Alessia Girello, Mario U. Mondelli, Fausto Baldanti. Baseline and Breakthrough Resistance Mutations in HCV Patients Failing DAAsScientific Reports 2017; 7(1) doi: 10.1038/s41598-017-15987-1
28
Elena Perpiñán, Noelia Caro-Pérez, Neris García-González, Josep Gregori, Patricia González, Concepción Bartres, Maria Eugenia Soria, Celia Perales, Sabela Lens, Zoe Mariño, María Carlota Londoño, Xavier Ariza, George Koutsoudakis, Josep Quer, Fernando González-Candelas, Xavier Forns, Sofía Pérez-del-Pulgar. Hepatitis C virus early kinetics and resistance-associated substitution dynamics during antiviral therapy with direct-acting antiviralsJournal of Viral Hepatitis 2018; 25(12): 1515 doi: 10.1111/jvh.12986
29
Timothy Papaluca, Stuart K Roberts, Simone I Strasser, Katherine A Stuart, Geoffrey Farrell, Gerry MacQuillan, Gregory J Dore, Amanda J Wade, Jacob George, Simon Hazeldine, James O’Beirne, Alan Wigg, Leslie Fisher, Bruce McGarity, Rohit Sawhney, Marie Sinclair, James Thomas, Ivan Valiozis, Martin Weltman, Mark Wilson, Aidan Woodward, Golo Ahlenstiel, Mazhar Haque, Miriam Levy, Emily Prewett, William Sievert, Siddharth Sood, Edmund Tse, Zina Valaydon, Scott Bowden, Mark Douglas, Kate New, Jacinta O’Keefe, Margaret Hellard, Joseph Doyle, Mark Stoove, Alexander J Thompson. Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients With Difficult to Cure CharacteristicsClinical Infectious Diseases 2021; 73(9): e3288 doi: 10.1093/cid/ciaa1318
30
Ahmed KAMAL, Cecil MATTA, Heba Akram MOHSIN, Abeer Shawki ELHADIDI, Ramy Mohamed GHAZY, Heba Hany OMAR, Mona TAHOUN, Nema Abdelhameed MOHAMED. ASSESSING PREDICTORS OF DIRECTLY ACTING ANTIVIRALS’ FAILURE AS A FURTHER STEP TOWARDS MORE EFFICIENT HCV ELIMINATION PROGRAMS: IL28B (IFNL4) GENE POLYMORPHISM HAS NO ROLE WHILE HIGHER ESTIMATED CREATININE CLEARANCE IS A FORGOTTEN FACTORArquivos de Gastroenterologia 2022; 59(2): 177 doi: 10.1590/s0004-2803.202202000-33
31
T. Semenova, B. Nemoz, V. Thibault, G. Lagathu, G. Duverlie, E. Brochot, P. Trimoulet, C. Payan, S. Vallet, C. Henquell, S. Chevaliez, M. Bouvier-Alias, S. Maylin, A-M. Roque-Afonso, L. Izquierdo, F. Lunel-Fabiani, P. Marcellin, P. Morand, V. Leroy, S. Larrat. Hepatitis C subtype distribution in chronically infected patients with mild liver fibrosis in France: the GEMHEP studyEpidemiology and Infection 2019; 147 doi: 10.1017/S0950268819001225
32
Jian-Hong Chen, Zheng Zeng, Xia-Xia Zhang, Yu Zhang, Ren-Wen Zhang, Shuai Wang, Chi-Hong Wu, Min Yu, Dan Liu, Hong-Li Xi, Yi-Xing Zhou, Yao-Yu An, Xiao-Yuan Xu. Efficacy and safety of combined directly acting antivirals for treatment of Chinese chronic hepatitis C patients in a real-world settingWorld Journal of Gastroenterology 2017; 23(22): 4072-4079 doi: 10.3748/wjg.v23.i22.4072
33
Linda Henry, Zobair Younossi. Patient-reported and economic outcomes related to sofosbuvir and ledipasvir treatment for chronic hepatitis CExpert Review of Pharmacoeconomics & Outcomes Research 2016; 16(6): 659 doi: 10.1080/14737167.2016.1244007
34
Bruna Forte Aguiar, Guilherme Rodrigues Fernandes Campos, João Paulo Vilela Rodrigues, Nayara Nathie Marques, Bárbara Floriano Molina, Cintia Bittar, Fernanda Fernandes Souza, Ana de Lourdes Candolo Martinelli, Paula Rahal, Leonardo Régis Leira Pereira. Baseline resistance associated substitutions in HCV genotype 1 infected cohort treated with Simeprevir, Daclatasvir and Sofosbuvir in BrazilClinics and Research in Hepatology and Gastroenterology 2020; 44(3): 329 doi: 10.1016/j.clinre.2019.07.015
35
Manar Ahmed, Azza E. Mansey, Engy A. Wahsh, Ahmed A. Gomaa, Hoda M. Rabea. Efficacy and Safety of Ombitasvir plus Paritaprevir, Ritonavir and Ribavirin in Non-cirrhotic Treatment-naïve and Treatment-experienced Egyptians with Chronic HCV Genotype-4 InfectionCurrent Medical Science 2021; 41(3): 581 doi: 10.1007/s11596-021-2363-9